EP0337601A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Porphyrins and medicaments for cancer treatment
Assignee: Bioscience Technology Investment Holdings Ltd
•
Filing: 1989-02-27
•
Granted: —
•
Expires: 2009-02-27
Abstract
Abstract This invention provides novel compounds for therapy of tumours suceptible to necrosis when an appropriate compound is adminstered followed by illumination with light of a wavelength absorbed by the compound, the compounds being dihydro porphyrins of the formula, or the corresponding tetra-hydro porphyrins: where n = 1 to 3 and each substituent R, the same or different and at the same or different position in its respective substituent phenyl ring, is an hydroxy group.
Inventors
- 👤 Raymond Bonnett
- 👤 Morris Cyril Berenbaum
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 15:54
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/22; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61P; A61P35/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
99 words
Compounds being pharmacologically acceptable tumour locating dihydro or tetra-hydro porphyrins of the formulae below; methods of making medicaments for therapy of tumours susceptible to necrosis when such a compound is administered to locate in the tumour followed by illumination of the tumour with light of a wavelength absorbed by the compound, said methods making use of the compounds by associating them with a pharmaceutical diluent or carrier; and such medicaments and therapy as such; the compounds being of the formulae:- wherein each Ar, the same or different, is an aromatic group with one or more hydroxy (-OH) substituent groups.
Claim 2
Dependent Claim
99 words
Compounds being pharmacologically acceptable tumour locating dihydro or tetra-hydro porphyrins of the formulae below; methods of making medicaments for therapy of tumours susceptible to necrosis when such a compound is administered to locate in the tumour followed by illumination of the tumour with light of a wavelength absorbed by the compound, said methods making use of the compounds by associating them with a pharmaceutical diluent or carrier; and such medicaments and therapy as such; the compounds being of the formulae:- wherein each Ar, the same or different, is an aromatic group with one or more hydroxy (-OH) substituent groups.
Claim 3
Dependent Claim
48 words
The subject matter of claim 1, the compounds being of the formula:- or the corresponding tetra-hydro porphyrins, where n = 1 to 3 and each substituent R, the same or different and at the same or different position in its respective substituent phenyl ring, is an hydroxy group.
Claim 4
Dependent Claim
19 words
The subject matter of claim 2 where each substituent is an o -hydroxyphenyl, m -hydroxyphenyl or p -hydroxyphenyl group.
Claim 5
Dependent Claim
21 words
The subject matter of claim 1, 2 or 3 wherein each hydroxy group is free rather than in a substituted form.
Claim 6
Dependent Claim
33 words
The subject matter of claims 1, 2, 3 or 4 the compounds being synthesis of 2,3-dihydro-5,10,15,20-tetra(p-hydroxy-phenyl) porphyrin; synthesis of 2,3-dihydro-5,10,15,20-tetra(m-hydroxy-phenyl) porphyrin; synthesis of 2,3-dihydro-5,10,15,20-tetra ( o -hydroxyphenyl) porphyrin and synthesis of 7,8,17,18-tetrahydro-5,10,15,20-tetra(m-hydroxyphenyl) porphyrin.
References Cited (Backward Citations)
EP0127797A1
Cited
EP0186962A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.